Recent Updates — CLDI

Calidi Biotherapeutics, Inc. closed a registered direct offering on September 21, 2026, selling 1,025,640 shares of common stock at $1.17 per share to generate approximately $1.2 million in gross proceeds. The company intends to use the net proceeds for working capital and general corporate purposes. No underwriter or placement agent was involved in the transaction. Calidi Biotherapeutics operates as a biotechnology company pioneering targeted genetic medicines using its RedTail platform.

Calidi Biotherapeutics, Inc. expanded its Board of Directors from five to six members by appointing Dr. Corazon (Corsee) Sanders as a Class III director with a term expiring at the 2029 annual meeting. Dr. Sanders will also serve on the Audit Committee, replacing Scott Leftwich on that committee. Calidi Biotherapeutics, Inc. is a biotechnology company focused on developing therapies for cancer and infectious diseases.

At its 2026 Annual Meeting of Stockholders on June 12, 2026, Calidi Biotherapeutics, Inc. stockholders approved an amendment to the certificate of incorporation to allow the Board of Directors to effect a reverse stock split within a range of 1-for-2 to 1-for-16. Stockholders also elected Scott Leftwich as a Class III Director and approved an appointment of CBIZ CPAs P.C. as the company's independent auditor. Calidi Biotherapeutics, Inc. is a biotechnology company focused on oncolytic virotherapy.***